Data from The British Journal of Cardiology - Curated by EPG Health - Last updated 07 September 2017
As so many of the common problems in clinical practice today relate to arterial and venous thrombosis, it is important that all healthcare professionals have a clear understanding of the basics of thrombosis/haemostasis and coagulation/anticoagulation pathways. The underlying final pathophysiological process in myocardial infarction and ischaemic stroke is thrombus formation (thrombogenesis). Other common cardiovascular disorders, such as atrial fibrillation (AF) and heart failure, are also associated with thrombogenesis.
In this updated and revised modular programme we will first be introduced to antithrombotic therapy by examining the mechanism of coagulation and how this relates to the development of arterial and venous thrombosis. Module two will discuss how and why antiplatelet therapy is important, and another module will look at the value of anticoagulant therapy. The latter two modules will be complimented by case studies.
Each module will have a series of multiple-choice questions. Its five hours of learning leads to five continuing professional development (CPD) credits.
The programme has been made available with an educational grant from Bristol Myers Squibb (BMS) and Pfizer UK Limited. It has been independently written by leading UK physicians and pharmacists, and has been endorsed by Anticoagulation Europe, the Atrial Fibrillation Association, and Arrhythmia Alliance – the Heart Rhythm Charity.
|Registration with provider required||Yes|
|Author(s)||Dr Andrew Blann, Dr Louise Tillyer, Mr Sotiris Antoniou, Dr Matthew Rogers.|
|Intended audience(s)||Medical Doctor|
|Assessment method(s)||Multiple choice|